Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2020

View Archived Issues

Microbiome metabolites as immunotherapy adjuvants

Oxygen therapy harms lungs via lung, gut microbiome

Positive preclinical data presented for multi-target COVID-19 vaccine

T-2143, a novel HSP90-PI3K drug conjugate with promising activity in cancer models

Discovery of a novel FASN inhibitor with promising activity in model of AD

BrightGene Bio-Medical Technology identifies Gly12Cys mutant GTPase KRAS inhibitors

New PD-1/PD-L1 and/or PD-L1/CD80 interaction inhibitors patented by Betta Pharmaceuticals

Jiangsu Vcare Pharmatech discovers JAK inhibitors

Zhejiang Hisun Pharmaceutical presents new RET inhibitors

University of Queensland, Preveceutical Medical patent delta- and kappa-opioid receptor antagonists

Update on development of PGX-YBG inhalable therapeutic for COVID-19

First patient dosed in phase Ib study of ARO-HIF2 in clear cell renal cell carcinoma

Topline data presented from phase II study of elobixibat in NAFLD and NASH

FDA issues complete response letter for filgotinib for the treatment of RA

Promising interim data presented from phase II study of ERC-1671 in recurrent GBM

Phase II study of QBECO SSI in colorectal cancer approved in Israel

Evotec and Novo Nordisk collaborate to develop novel therapies for CKD

Targeting the adenosine A2A receptor may prevent osteoarthritis progression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...